Trial Profile
A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-Type After 6 Cycles of Combination Therapy With mFOLFOX6+Panitumumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Levofolinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms SAPPHIRE
- Sponsors Takeda
- 12 Aug 2019 Primary endpoint has been met. (Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization), according to results published in the European Journal of Cancer.
- 12 Aug 2019 Results published in the European Journal of Cancer.
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium